

# Carlo Salvarani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/203805/publications.pdf>

Version: 2024-02-01

530  
papers

32,593  
citations

5896

81  
h-index

6131

159  
g-index

539  
all docs

539  
docs citations

539  
times ranked

17745  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet's Uveitis: Customizing Therapy according to the Clinical Features. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 506-514.	1.8	11
2	Clinical Relevance of Subcentimetric Lymph Node Biopsy in the Diagnosis of Ocular Sarcoidosis. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 717-720.	1.8	3
3	Efficacy and safety of TNF- $\alpha$ antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384.	1.9	26
4	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 346-353.	6.5	2
5	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. <i>Rheumatology</i> , 2022, 61, 2915-2922.	1.9	24
6	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	2.0	12
7	VECTOR: An algorithm for the detection of COVID-19 pneumonia from velcro-like lung sounds. <i>Computers in Biology and Medicine</i> , 2022, 142, 105220.	7.0	11
8	Vessel inflammation and morphological changes in patients with large vessel vasculitis: a retrospective study. <i>RMD Open</i> , 2022, 8, e001977.	3.8	7
9	Clinical Features and Prevalence of Spondyloarthritis in a Cohort of Italian Patients Presenting with Acute Nongranulomatous Anterior Uveitis. <i>Journal of Immunology Research</i> , 2022, 2022, 1-9.	2.2	3
10	Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 621.	2.4	9
11	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 393-399.	5.6	71
12	Acute exacerbation of interstitial lung disease associated with rheumatic disease. <i>Nature Reviews Rheumatology</i> , 2022, 18, 85-96.	8.0	28
13	Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 335.	2.5	2
14	Inflammatory burden and persistent CT lung abnormalities in COVID-19 patients. <i>Scientific Reports</i> , 2022, 12, 4270.	3.3	5
15	Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers. <i>Rheumatology and Therapy</i> , 2022, 9, 891-905.	2.3	8
16	Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 653-661.	0.9	49
17	The role of PET/CT in disease activity assessment in patients with large vessel vasculitis. <i>Rheumatology</i> , 2022, 61, 4809-4816.	1.9	22
18	Vasculitis, fibromuscular dysplasia or hereditary aneurysms?. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0

#	ARTICLE	IF	CITATIONS
19	Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. <i>Rheumatology and Therapy</i> , 2022, 9, 521-539.	2.3	18
20	Use of Ultrasonography to Discriminate Psoriatic Arthritis from Fibromyalgia: A Post-Hoc Analysis of the ULISSE Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 180.	2.4	4
21	Mortality Prediction of COVID-19 Patients Using Radiomic and Neural Network Features Extracted from a Wide Chest X-ray Sample Size: A Robust Approach for Different Medical Imbalanced Scenarios. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 3903.	2.5	9
22	Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210903.	2.7	7
23	Follow-Up CT Patterns of Residual Lung Abnormalities in Severe COVID-19 Pneumonia Survivors: A Multicenter Retrospective Study. <i>Tomography</i> , 2022, 8, 1184-1195.	1.8	19
24	Rehabilitation Interventions for Post-Acute COVID-19 Syndrome: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5185.	2.6	95
25	Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	6
26	Comparing treatment options for large vessel vasculitis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 793-805.	3.0	7
27	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
28	Could different aqueous humor and plasma cytokine profiles help differentiate between ocular sarcoidosis and ocular tuberculosis?. <i>Inflammation Research</i> , 2022, 71, 949-961.	4.0	4
29	Apremilast retention rate in clinical practice: observations from an Italian multi-center study. <i>Clinical Rheumatology</i> , 2022, 41, 3219-3225.	2.2	3
30	Heritable and non-heritable uncommon causes of stroke. <i>Journal of Neurology</i> , 2021, 268, 2780-2807.	3.6	27
31	Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2021, 73, 402-408.	3.4	18
32	Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia. <i>JAMA Internal Medicine</i> , 2021, 181, 24.	5.1	593
33	Invited Response on: Comments on "Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study". <i>Aesthetic Plastic Surgery</i> , 2021, 45, 1344-1345.	0.9	1
34	Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. <i>Drugs in Context</i> , 2021, 10, 1-17.	2.2	8
35	Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2021, 15, 117954842110013.	0.9	4
36	Autologous fat grafting in the treatment of a scleroderma stump-skin ulcer: a case report. <i>Case Reports in Plastic Surgery &amp; Hand Surgery</i> , 2021, 8, 18-22.	0.3	5

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. <i>Drugs in Context</i> , 2021, 10, 1-12.	2.2	10
38	Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. <i>RMD Open</i> , 2021, 7, e001519.	3.8	32
39	Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases. <i>Rheumatology</i> , 2021, 60, e285-e287.	1.9	0
40	Comments on: "Unexpected detection of SARS-CoV-2 antibodies in the pre-pandemic period in Italy". <i>Tumori</i> , 2021, 107, 030089162199243.	1.1	1
41	Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-6.	1.8	6
42	Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis. <i>Case Reports in Medicine</i> , 2021, 2021, 1-5.	0.7	21
43	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. <i>Rheumatology</i> , 2021, 60, S125-S136.	1.9	13
44	The management of large vessel vasculitides. <i>Beyond Rheumatology</i> , 2021, 3, .	0.3	0
45	Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. <i>Rheumatology</i> , 2021, 60, 3851-3861.	1.9	38
46	Rheumatoid arthritis related interstitial lung disease. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 485-497.	3.0	18
47	AB0425...CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1241.1-1241.	0.9	0
48	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e328-e336.	3.9	52
49	OP0310...GENDER AND FIBROMYALGIA SEVERITY: REAL LIFE DATA FROM THE ITALIAN REGISTRY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 190-191.	0.9	0
50	Cataract Surgery with Intraocular Lens Implantation in Juvenile Idiopathic Arthritis-Associated Uveitis: Outcomes in the Era of Biological Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2437.	2.4	4
51	POS0837...THE USE OF CANNABIDIOL IN THE TREATMENT OF PAIN RELATED TO SCLERODERMA DIGITAL ULCERS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 672.2-673.	0.9	0
52	Genetic Association of a Gain-of-Function <i>IFNGR1</i> Polymorphism and the Intergenic Region <i>LNCAROD/DKK1</i> With Behçet's Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1244-1252.	5.6	21
53	POS0927...EFFECTIVENESS AND SAFETY OF SECUKINUMAB IN NAÏVE OR TNF-INHIBITORS FAILURE AXIAL SPONDYLOARTHRITIS PATIENTS IN REAL LIFE: A 24-MONTHS PROSPECTIVE MULTICENTRIC STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 726.1-726.	0.9	0
54	AB0716...FIBROMYALGIA SYNDROME SEVERITY ACCORDING TO AGE CATEGORIES: RESULTS FROM A NATIONAL REGISTER. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1389.2-1390.	0.9	0

#	ARTICLE	IF	CITATIONS
55	AB0522â€¦SAFETY PROFILE OF LIPADACITINIB UP TO 3 YEARS IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS FROM THE PHASE 3 PROGRAM. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1287-1288.	0.9	3
56	The impact of chest CT body composition parameters on clinical outcomes in COVID-19 patients. <i>PLoS ONE</i> , 2021, 16, e0251768.	2.5	26
57	Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials. <i>Rheumatology and Therapy</i> , 2021, 8, 1435-1441.	2.3	15
58	Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association. <i>Journal of Clinical Medicine</i> , 2021, 10, 2548.	2.4	8
59	Sensing Inflammation Biomarkers with Electrolyteâ€Gated Organic Electronic Transistors. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100955.	7.6	16
60	Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 786-792.	3.4	16
61	Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-9.	1.8	3
62	18F-FDG PET-CT versus contrast enhanced CT for the diagnosis of fever of unknown origin. <i>European Journal of Internal Medicine</i> , 2021, 93, 26-27.	2.2	1
63	Response to â€The Relevance of Restricted Inflammation in a TABâ€™™ by Griffin KJ etâ€™Al.. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, e8-e9.	3.4	1
64	Sensitivity to change and clinical correlations of the novel DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 4103-4111.	1.9	5
65	Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential. <i>Biomedicines</i> , 2021, 9, 17.	3.2	12
66	Ultrasound Effectiveness of Steroid Injection for hand Psoriatic Dactylitis: Results from a Longitudinal Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1809-1826.	2.3	3
67	Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. <i>Rheumatology and Therapy</i> , 2021, 8, 1789-1808.	2.3	14
68	Usefulness of Digital Velcro Crackles Detection in Identification of Interstitial Lung Disease in Patients With Connective Tissue Diseases. <i>Archives of Rheumatology</i> , 2021, 36, 19-25.	0.9	5
69	New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine?. <i>Lancet Rheumatology, The</i> , 2021, 3, e874-e885.	3.9	8
70	Systemic sclerosis cutaneous expression: Management of skin fibrosis and digital ulcers. <i>Annals of Medicine and Surgery</i> , 2021, 71, 102984.	1.1	11
71	Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells. <i>Stem Cell Research and Therapy</i> , 2021, 12, 598.	5.5	21
72	High-dose glucocorticoids pulse-therapy for beta-coronaviridae pneumonia: a systematic literature review and case-series of Coronavirus disease-2019. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1119-1125.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 129-134.	0.8	1
74	Methylprednisolone as rescue therapy after tocilizumab failure in patients with severe COVID-19 pneumonia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1141.	0.8	0
75	Interstitial lung disease in ANCA-associated vasculitis: another step forward. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 193.	0.8	0
76	Reply to the comment on: Hypereosinophilic bronchiolitis in ANCA-associated vasculitis: where does it stand? by Bilgin et al. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 197.	0.8	0
77	Reply to the comment on: Hypereosinophilic bronchiolitis in ANCA-associated vasculitis: where does it stand? by Bilgin et al.. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 197-197.	0.8	0
78	Interstitial lung disease in ANCA-associated vasculitis: another step forward. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 193-193.	0.8	1
79	Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 769870.	2.6	6
80	Uveitis and Other Ocular Complications Following COVID-19 Vaccination. <i>Journal of Clinical Medicine</i> , 2021, 10, 5960.	2.4	92
81	Ultrasonographic Evidence of Predominance of Acute Extracapsular and Chronic Intrasynovial Patterns in 100 Cases of Psoriatic Hand Dactylitis. <i>Journal of Rheumatology</i> , 2020, 47, 227-233.	2.0	18
82	Interferon Alpha-2a Treatment for Post-Uveitic Refractory Macular Edema. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 322-328.	1.8	15
83	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.9	667
84	Predominant ultrasonographic extracapsular changes in symptomatic psoriatic dactylitis: results from a multicenter cross-sectional study comparing symptomatic and asymptomatic hand dactylitis. <i>Clinical Rheumatology</i> , 2020, 39, 1157-1165.	2.2	19
85	Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. <i>Internal Medicine Journal</i> , 2020, 50, 1085-1090.	0.8	75
86	Vasculitis in a patient with mixed cryoglobulinemia treated with rituximab biosimilar CT-P10: a case report. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 102-105.	0.7	1
87	Interstitial pneumonia with autoimmune features: A single center prospective follow-up study. <i>Autoimmunity Reviews</i> , 2020, 19, 102451.	5.8	34
88	Use of Neem oil and <i>Hypericum perforatum</i> for treatment of calcinosis-related skin ulcers in systemic sclerosis. <i>Journal of International Medical Research</i> , 2020, 48, 030006051988217.	1.0	15
89	Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3033.	2.4	4
90	Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. <i>Critical Care</i> , 2020, 24, 589.	5.8	47

#	ARTICLE	IF	CITATIONS
91	COVID-19-associated vasculitis and thrombotic complications: from pathological findings to multidisciplinary discussion. <i>Rheumatology</i> , 2020, 59, e147-e150.	1.9	19
92	Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study. <i>Aesthetic Plastic Surgery</i> , 2020, 44, 1820-1832.	0.9	23
93	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. <i>Lancet</i> , The, 2020, 396, 267-276.	13.7	78
94	Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 751-770.	3.0	10
95	TOCID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. <i>Contemporary Clinical Trials</i> , 2020, 98, 106165.	1.8	9
96	Cardiac involvement in the adult primary vasculitides. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 985-991.	3.0	5
97	Lung complications of Sjogren syndrome. <i>European Respiratory Review</i> , 2020, 29, 200021.	7.1	31
98	Effectiveness of steroid injection for hand psoriatic dactylitis: results from a multicentre prospective observational study. <i>Clinical Rheumatology</i> , 2020, 39, 3383-3392.	2.2	10
99	Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 549-558.	3.4	29
100	Susceptibility and severity of COVID-19 in patients treated with bDMARDs and tsDMARDs: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 986.2-988.	0.9	49
101	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-6.	3.0	7
102	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e474-e484.	3.9	772
103	Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 358.	4.8	36
104	Ultrasonographic and clinical assessment of peripheral enthesitis and arthritis in an Italian cohort of inflammatory bowel disease patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 436-443.	3.4	8
105	Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 407.	2.4	40
106	Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study. <i>Rheumatology and Therapy</i> , 2020, 7, 301-310.	2.3	11
107	Long-term remission, relapses and maintenance therapy in adult primary central nervous system vasculitis: A single-center 35-year experience. <i>Autoimmunity Reviews</i> , 2020, 19, 102497.	5.8	29
108	Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 277.	2.4	44



#	ARTICLE	IF	CITATIONS
109	Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. <i>Journal of Clinical Medicine</i> , 2020, 9, 1082.	2.4	68
110	Citelman syndrome associated with chondrocalcinosis and severe neuropathy: a novel heterozygous mutation in SLC12A3 gene. <i>Reumatismo</i> , 2020, 72, 67-70.	0.9	5
111	The Italian Society of Rheumatology clinical practice guidelines for the management of polymyalgia rheumatica. <i>Reumatismo</i> , 2020, 72, 1-15.	0.9	9
112	Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?. <i>Respiratory Medicine Case Reports</i> , 2020, 30, 101051.	0.4	4
113	Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease. <i>Case Reports in Medicine</i> , 2020, 2020, 1-4.	0.7	9
114	Reading and interpreting reviews for health professionals: a practical review. <i>Internal and Emergency Medicine</i> , 2020, 15, 945-955.	2.0	3
115	Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 609204.	3.7	22
116	Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1064-1072.	3.4	22
117	THU0600â€¦A CASE OF SYSTEMIC SCLEROSIS COMPLICATED BY RENAL CRISIS: POTENTIAL ETIOPATHOGENETIC ROLE OF CYTOMEGALOVIRUS AND TREATMENT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 542.1-542.	0.9	1
118	Musculoskeletal Ultrasound in Monitoring Clinical Response to Treatment in Acute Symptomatic Psoriatic Dactylitis: Results from a Multicentre Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3127.	2.4	6
119	AB0039â€¦ROLE OF MESENCHYMAL STEM CELLS ISOLATED FROM DENTAL PULP (DPSCS) IN IMMUNOREGULATION PROCESSES MEDIATED BY PROGRAMMED DEATH-LIGAND 1 (PD-L1). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1322.1-1322.	0.9	1
120	FRI0212â€¦THE ROLE OF AGE ON THE CLINICAL PRESENTATION AND RELAPSE RATES IN A LARGE COHORT OF 720 PATIENTS WITH GIANT CELL ARTERITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 689.1-690.	0.9	0
121	THU0298â€¦SWITCH OR SWAP STRATEGY IN TAKAYASU ARTERITIS PATIENTS FAILING TNFA INHIBITORS?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 377-377.	0.9	0
122	An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 107-114.	0.8	6
123	Imbalance between angiogenic and anti-angiogenic factors in sera from patients with large-vessel vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 23-30.	0.8	3
124	Enthesitis and small cell lung carcinoma: a novel paraneoplastic syndrome not previously described. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 372.	0.8	0
125	Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 79-83.	0.8	1
126	Association between Leeds Dactylitis Index and ultrasonographic features: a multicentre study on psoriatic hand dactylitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1112-1117.	0.8	3



#	ARTICLE	IF	CITATIONS
127	Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 221-231.	0.8	14
128	Interstitial lung disease in Sjögren's syndrome: a clinical review. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 291-300.	0.8	7
129	Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia. Clinical and Experimental Rheumatology, 2020, 38, 1215-1222.	0.8	3
130	Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. Seminars in Arthritis and Rheumatism, 2019, 48, 752-762.	3.4	56
131	New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. Internal and Emergency Medicine, 2019, 14, 1193-1197.	2.0	13
132	Magnetic resonance angiography versus 18F-fluorodeoxyglucose positron emission tomography in large vessel vasculitis. Autoimmunity Reviews, 2019, 18, 102405.	5.8	19
133	Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. Journal of Thoracic Disease, 2019, 11, 1621-1628.	1.4	45
134	Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRATe validation study (INterSTitial pneumonia in rheumatoid Arthritis with) Tj ETQq0 0 0zgb /Overlock 10 Tf		
135	Large-Vessel Vasculitis. , 2019, , 609-618.		1
136	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1160-1166.	0.9	34
137	Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis and Rheumatology, 2019, 71, 1329-1338.	5.6	74
138	<sup>64</sup> Cu and fluorescein labeled anti-miRNA peptide nucleic acids for the detection of miRNA expression in living cells. Scientific Reports, 2019, 9, 3376.	3.3	13
139	Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study. Journal of Rheumatology, 2019, 46, 904-911.	2.0	58
140	The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review. Rheumatology International, 2019, 39, 971-990.	3.0	38
141	Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature. Autoimmunity Reviews, 2019, 18, 399-405.	5.8	17
142	FRI0613â€¦THERAPEUTIC STRATEGIES AND SURVIVAL IN PATIENTS WITH INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES. , 2019, , .		0
143	AB0212â€¦LONG-TERM TREATMENT WITH RITUXIMAB IN SYSTEMIC SCLEROSISMANAGEMENT: AN OVERVIEW OF THE CLINICAL EXPERIENCE FROM A REAL-LIFE SETTING. , 2019, , .		0
144	THU0349â€¦AUTOLOGOUS FAT GRAFTING IN THE TREATMENT OF PATIENTS WITH SYSTEMIC SCLEROSIS: CURRENT EXPERIENCE AND FUTURE PROSPECTS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
145	FRI0284â€¦RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS. , 2019, , .		1
146	Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 1497.	3.5	12
147	Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. <i>RMD Open</i> , 2019, 5, e001003.	3.8	52
148	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. <i>RMD Open</i> , 2019, 5, e001020.	3.8	56
149	Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. <i>Clinical and Experimental Immunology</i> , 2019, 196, 123-138.	2.6	27
150	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. <i>Autoimmunity Reviews</i> , 2019, 18, 164-176.	5.8	44
151	Symptomatic psoriatic dactylitis is associated with ultrasound determined extra-synovial inflammatory features and shorter disease duration. <i>Clinical Rheumatology</i> , 2019, 38, 903-911.	2.2	21
152	The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2019, 98, 113-121.	6.5	7
153	â€œDisease knowledge indexâ€•and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. <i>Joint Bone Spine</i> , 2019, 86, 475-481.	1.6	25
154	Primary central nervous system vasculitis mimicking brain tumor: Comprehensive analysis of 13 cases from a single institutional cohort of 191 cases. <i>Journal of Autoimmunity</i> , 2019, 97, 22-28.	6.5	20
155	Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1074-1082.	3.4	40
156	Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study. <i>Rheumatology</i> , 2019, 58, 609-616.	1.9	26
157	Management of large-vessel vasculitis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 25-31.	4.3	14
158	Interferon Alpha-2a for the Treatment of Post-Infectious Uveitis Secondary to Presumed Intraocular Tuberculosis. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 643-650.	1.8	13
159	Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis: a Delphi consensus statement. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 575-584.	0.8	10
160	Interleukin-6 expression in inflamed and non-inflamed temporal arteries from patients with giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 98-103.	0.8	0
161	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018, 35, 545-562.	2.9	16
162	Tocilizumab for the treatment of giant cell arteritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 339-349.	3.0	23

#	ARTICLE	IF	CITATIONS
163	Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients. <i>Journal of Autoimmunity</i> , 2018, 91, 55-60.	6.5	59
164	2018 update of the EULAR recommendations for the management of Behçet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213225.	0.9	442
165	Primary central nervous system vasculitis associated with lymphoma. <i>Neurology</i> , 2018, 90, e847-e855.	1.1	22
166	The Sex Influence on Response to Tumor Necrosis Factor- $\alpha$ Inhibitors and Remission in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018, 45, 195-201.	2.0	32
167	EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 636-643.	0.9	753
168	Large Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease?. <i>Arthritis Care and Research</i> , 2018, 70, 1406-1411.	3.4	23
169	Colonic perforation due to severe cytomegalovirus disease in granulomatosis with polyangiitis after immunosuppression. <i>Clinical Rheumatology</i> , 2018, 37, 1427-1432.	2.2	8
170	CD3 immunohistochemistry is helpful in the diagnosis of giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 1377-1380.	1.9	8
171	Response to: 'Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries' by Graver et al. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e17-e17.	0.9	2
172	Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. <i>Rheumatology</i> , 2018, 57, 1151-1155.	1.9	50
173	Increased expression of interleukin-22 in patients with giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 64-72.	1.9	20
174	Usefulness of PET in recognizing and managing vasculitides. <i>Current Opinion in Rheumatology</i> , 2018, 30, 24-29.	4.3	10
175	Unmet Needs in the Pathogenesis and Treatment of Vasculitides. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 244-260.	6.5	21
176	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 515-528.	2.4	15
177	The Sex Influence on Response to Tumor Necrosis Factor- $\alpha$ Inhibitors and Remission in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018, 45, 195-201.	2.0	66
178	Cardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Large-vessel Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2018, 45, 1603-1604.	2.0	2
179	Nailfold videocapillaroscopy in antisynthetase syndrome. <i>Reumatismo</i> , 2018, 70, 257-258.	0.9	3
180	Standardization of red flags for referral to rheumatologists and ophthalmologists in patients with rheumatic diseases and ocular involvement: a consensus statement. <i>Rheumatology International</i> , 2018, 38, 1727-1734.	3.0	7

#	ARTICLE	IF	CITATIONS
181	Polymyalgia rheumatica: an autoinflammatory disorder?. RMD Open, 2018, 4, e000694.	3.8	15
182	Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica. Reumatismo, 2018, 70, 18-22.	0.9	13
183	Imaging in polymyalgia rheumatica. Reumatismo, 2018, 70, 51-58.	0.9	8
184	Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. Rheumatology, 2018, 57, 2200-2212.	1.9	89
185	Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. Journal of Rheumatology, 2018, 45, 1256-1262.	2.0	10
186	FRI0504...Diffuse alveolar haemorrhage in anca-associated vasculitis: can we predict outcome? an italian multicentre retrospective long-term study of 102 patients. , 2018, , .		0
187	AB0760...Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution. , 2018, , .		0
188	Contrast-Enhanced Ultrasound of the Carotid Artery in Patients With Large Vessel Vasculitis: Correlation With Positron Emission Tomography Findings. Arthritis Care and Research, 2017, 69, 143-149.	3.4	64
189	Incidence, Prevalence, and Survival of Biopsy-Proven Giant Cell Arteritis in Northern Italy During a 26-Year Period. Arthritis Care and Research, 2017, 69, 430-438.	3.4	55
190	Standard and biological treatment in large vessel vasculitis: guidelines and current approaches. Expert Review of Clinical Immunology, 2017, 13, 345-360.	3.0	29
191	Analysis of the common genetic component of large-vessel vasculitides through a meta-immunochip strategy. Scientific Reports, 2017, 7, 43953.	3.3	52
192	Ectopic expression of CXCL13, BAFF, APRIL and LT- $\alpha$ is associated with artery tertiary lymphoid organs in giant cell arteritis. Annals of the Rheumatic Diseases, 2017, 76, 235-243.	0.9	67
193	No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis. Seminars in Arthritis and Rheumatism, 2017, 47, 235-240.	3.4	35
194	New insights into the pathogenesis of giant cell arteritis. Autoimmunity Reviews, 2017, 16, 675-683.	5.8	51
195	Do we need FDG-PET/CT to assess atherosclerosis?. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 247-248.	6.4	3
196	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
197	Is PET/CT essential in the diagnosis and follow-up of temporal arteritis?. Autoimmunity Reviews, 2017, 16, 1125-1130.	5.8	35
198	Trial of Tocilizumab in Giant-Cell Arteritis. New England Journal of Medicine, 2017, 377, 317-328.	27.0	974

#	ARTICLE	IF	CITATIONS
199	Ignazio Olivieri, MD, 1953â€“2017. <i>Journal of Rheumatology</i> , 2017, 44, 1682-1682.	2.0	0
200	Visual loss and other cranial ischaemic complications in giant cell arteritis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 476-484.	8.0	121
201	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. <i>Digestive and Liver Disease</i> , 2017, 49, 1298-1305.	0.9	13
202	Efficacy and safety of adalimumab in Behçetâ€™s disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 183-189.	2.2	84
203	Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 657-664.	3.4	62
204	Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study. <i>Journal of Autoimmunity</i> , 2017, 77, 39-44.	6.5	27
205	Clinical Spectrum of Mediumâ€“Sized Vessel Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 884-891.	3.4	33
206	Behçetâ€™s Disease. , 2017, , 505-526.		0
207	Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DELphi in psoriatic Arthritis (IDEA). <i>Reumatismo</i> , 2016, 68, 126-136.	0.9	15
208	Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0149579.	2.5	18
209	Anti-TNF-Î± Drugs Differently Affect the TNF-Î±-sTNFR System and Monocyte Subsets in Patients with Psoriasis. <i>PLoS ONE</i> , 2016, 11, e0167757.	2.5	27
210	Imaging Findings of Cerebral Amyloid Angiopathy, AÎ²-Related Angiitis (ABRA), and Cerebral Amyloid Angiopathyâ€“Related Inflammation. <i>Medicine (United States)</i> , 2016, 95, e3613.	1.0	86
211	Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy. <i>Medicine (United States)</i> , 2016, 95, e3524.	1.0	78
212	Management of primary and secondary central nervous system vasculitis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 21-28.	4.3	27
213	Recent advances in the diagnosis and treatment of polymyalgia rheumatica. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1037-1045.	3.0	13
214	Impact of training on concordance among rheumatologists and dermatologists in the assessment of patients with psoriasis and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 305-311.	3.4	12
215	Imaging of vasculitis: State of the art. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 688-706.	3.3	64
216	Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study. <i>Journal of Rheumatology</i> , 2016, 43, 1541-1546.	2.0	14

#	ARTICLE	IF	CITATIONS
217	Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study. <i>Arthritis Care and Research</i> , 2016, 68, 865-870.	3.4	26
218	IgG4-Related Sacroiliitis. <i>Arthritis and Rheumatology</i> , 2016, 68, 774-774.	5.6	6
219	Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis. <i>Journal of Autoimmunity</i> , 2016, 69, 94-101.	6.5	33
220	Biotherapies in large vessel vasculitis. <i>Revue De Medecine Interne</i> , 2016, 37, 274-278.	1.0	5
221	MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1527-1533.	0.9	37
222	Polyarteritis Nodosa. , 2016, , 189-196.		1
223	Adult Primary Central Nervous System Vasculitis. , 2016, , 245-257.		4
224	Cogan's Syndrome. , 2016, , 749-754.		0
225	Whole exome sequencing identifies rare protein-coding variants in Behçet's disease. <i>Arthritis and Rheumatology</i> , 2015, 68, n/a-n/a.	5.6	9
226	An Update of the Mayo Clinic Cohort of Patients With Adult Primary Central Nervous System Vasculitis. <i>Medicine (United States)</i> , 2015, 94, e738.	1.0	133
227	Biologics in vasculitides: Where do we stand, where do we go from now?. <i>Presse Medicale</i> , 2015, 44, e231-e239.	1.9	5
228	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2569-2580.	5.6	146
229	Tocilizumab for severe refractory neuro-Behçet: Three cases IL-6 blockade in neuro-Behçet. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 472-475.	3.4	75
230	Adult Primary Central Nervous System Vasculitis Treatment and Course: Analysis of One Hundred Sixty-Three Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 1637-1645.	5.6	118
231	Nailfold capillaroscopic changes in dermatomyositis and polymyositis. <i>Clinical Rheumatology</i> , 2015, 34, 279-284.	2.2	64
232	Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?. <i>Rheumatology</i> , 2015, 54, 2004-2009.	1.9	32
233	Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. <i>Journal of Autoimmunity</i> , 2015, 62, 67-74.	6.5	178
234	Rheumatic Manifestations of Scurvy. <i>Current Rheumatology Reports</i> , 2015, 17, 26.	4.7	13

#	ARTICLE	IF	CITATIONS
235	Mycophenolate mofetil in primary central nervous system vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 55-59.	3.4	30
236	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
237	Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. <i>Rheumatology</i> , 2015, 54, 1596-1604.	1.9	66
238	The Role of Tumor Necrosis Factor- $\hat{A}$ Blockers in Psoriatic Disease. <i>Therapeutic Options in Psoriatic Arthritis. Journal of rheumatology Supplement, The</i> , 2015, 93, 73-78.	2.2	12
239	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1799-1807.	0.9	220
240	Remission in Nonradiographic Axial Spondyloarthritis Treated with Anti-tumor Necrosis Factor- $\hat{I}$ ± Drugs: An Italian Multicenter Study. <i>Journal of Rheumatology</i> , 2015, 42, 258-263.	2.0	37
241	Frequency of monoclonal gammopathy in psoriatic patients receiving anti- $\hat{S}$ cp>TNF</sc> therapy compared with patients taking conventional drugs: a cross- $\hat{E}$ sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2262-2263.	2.4	9
242	Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study. <i>Rheumatology</i> , 2015, 54, 400-404.	1.9	58
243	Large-vessel giant cell arteritis: a cohort study. <i>Rheumatology</i> , 2015, 54, 463-470.	1.9	245
244	Cyclosporine in psoriatic arthropathy. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S101-3.	0.8	5
245	Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNF $\hat{I}$ ± drugs. <i>Reumatismo</i> , 2014, 66, 208-214.	0.9	11
246	Influence of the<i>IL17A locus</i>in giant cell arteritis susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1742-1745.	0.9	36
247	The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 1-10.	2.1	69
248	Adalimumab in the Treatment of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 33-48.	2.1	65
249	Clinical images: PET-CT and contrast-enhanced ultrasound in Takayasu's arteritis. <i>Rheumatology</i> , 2014, 53, 447-447.	1.9	10
250	Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 11-32.	2.1	50
251	The INTERnational Study on Primary Angiitis of the CEntral Nervous System â€“ A Call to the World. <i>International Journal of Stroke</i> , 2014, 9, E23-E23.	5.9	7
252	Inflamed Temporal Artery. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1360-1370.	3.7	147



#	ARTICLE	IF	CITATIONS
253	Epidemiology of granulomatosis with polyangiitis (Wegener's granulomatosis) in Northern Italy: A 15-year population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 202-207.	3.4	30
254	The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 338-347.	2.4	977
255	Therapeutic Options After Treatment Failure in Rheumatoid Arthritis or Spondyloarthritis. <i>Advances in Therapy</i> , 2014, 31, 780-802.	2.9	2
256	Treatment of primary CNS vasculitis with rituximab: Case report. <i>Neurology</i> , 2014, 82, 1287-1288.	1.1	44
257	Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1190-1193.	0.9	81
258	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. <i>Joint Bone Spine</i> , 2014, 81, 508-512.	1.6	21
259	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014, 53, 2209-2213.	1.9	67
260	Canakinumab in a case of Adult onset Still's disease: Efficacy only on systemic manifestations. <i>Joint Bone Spine</i> , 2014, 81, 376-377.	1.6	34
261	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 822-830.	5.8	84
262	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. <i>PLoS ONE</i> , 2014, 9, e113476.	2.5	17
263	Skin Manifestations in Giant Cell Arteritis. , 2014, , 337-342.		0
264	Skin Manifestations in Microscopic Polyangiitis. , 2014, , 313-319.		0
265	Epidemiology of Behçet Syndrome. <i>Rare Diseases of the Immune System</i> , 2014, , 17-24.	0.1	1
266	Catastrophic primary central nervous system vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S3-4.	0.8	8
267	Searching for viral antibodies and genome in intraocular fluids of patients with Fuchs uveitis and non-infectious uveitis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 1607-1612.	1.9	21
268	IL-23A, IL-23R, IL-17A and IL-17R polymorphisms in different psoriatic arthritis clinical manifestations in the northern Italian population. <i>Rheumatology International</i> , 2013, 33, 1165-1176.	3.0	31
269	L30. Assessment of vasculitis extent and severity. <i>Presse Medicale</i> , 2013, 42, 588-589.	1.9	2
270	Role of Imaging in the Diagnosis of Large and Medium-Sized Vessel Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, 593-608.	1.9	24

#	ARTICLE	IF	CITATIONS
271	Remission in ankylosing spondylitis treated with anti-TNF- $\alpha$ drugs: a national multicentre study. <i>Rheumatology</i> , 2013, 52, 1914-1919.	1.9	60
272	Golimumab: A Novel Anti-Tumor Necrosis Factor. <i>Biologics in Therapy</i> , 2013, 3, 83-107.	1.8	6
273	Brief Report: Interleukin-6 as an Inflammatory Mediator and Target of Therapy in Chronic Periaortitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2469-2475.	6.7	51
274	Obesity and reduction of the response rate to anti-tumor necrosis factor $\alpha$ in rheumatoid arthritis: An approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013, 65, 94-100.	3.4	170
275	Update on polymyalgia rheumatica. <i>European Journal of Internal Medicine</i> , 2013, 24, 583-589.	2.2	31
276	Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. <i>Nature Genetics</i> , 2013, 45, 319-324.	21.4	130
277	Tocilizumab for polymyalgia rheumatica: Report of two cases and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 113-118.	3.4	59
278	$\text{A}\beta$ -related angiitis. <i>Neurology</i> , 2013, 81, 1596-1603.	1.1	163
279	Evidence of association of the <i>NLRP1</i> gene with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 628-630.	0.9	23
280	Is 18F Fluorodeoxyglucose Positron Emission Tomography Useful to Assess Activity of Myositis?. <i>Journal of Rheumatology</i> , 2013, 40, 912-91.	2.0	2
281	IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 258-264.	0.9	55
282	Comparison between colour duplex sonography findings and different histological patterns of temporal artery. <i>Rheumatology</i> , 2013, 52, 2268-2274.	1.9	48
283	NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1852-1859.	0.9	44
284	CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis. <i>Modern Rheumatology</i> , 2013, 23, 851-855.	1.8	3
285	Possible left endoventricular myxoma in a patient with deep vein thrombosis of the lower limbs: a case report. <i>Italian Journal of Medicine</i> , 2013, , 184-189.	0.3	0
286	TLR-4 and VEGF Polymorphisms in Chronic Periaortitis. <i>PLoS ONE</i> , 2013, 8, e62330.	2.5	8
287	CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis. <i>Modern Rheumatology</i> , 2013, 23, 851-855.	1.8	2
288	Lumbar interspinous bursitis in active polymyalgia rheumatica. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 526-31.	0.8	18

#	ARTICLE	IF	CITATIONS
289	Scurvy mimicking spondyloarthritis in a young man. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 795.	0.8	1
290	Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, S86-92.	0.8	6
291	2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 484-492.	0.9	451
292	CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. <i>Rheumatology</i> , 2012, 51, 2141-2145.	1.9	12
293	Adult primary central nervous system vasculitis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 46-52.	4.3	52
294	Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. <i>Rheumatology</i> , 2012, 51, 730-734.	1.9	72
295	Myocardial Positron Emission Tomography/Computed Tomography Scan Revealing Right Coronary Artery Involvement in Large Vessel Vasculitis. <i>Journal of Rheumatology</i> , 2012, 39, 1761.2-1763.	2.0	0
296	[18F]fluorodeoxyglucose positron emission tomography imaging in a case of relapsing polychondritis. <i>Rheumatology</i> , 2012, 51, 1813-1813.	1.9	7
297	Tocilizumab: a novel therapy for patients with large-vessel vasculitis. <i>Rheumatology</i> , 2012, 51, 151-156.	1.9	203
298	Adult primary central nervous system vasculitis. <i>Lancet, The</i> , 2012, 380, 767-777.	18.7	247
299	Identification of the Clinical Features Distinguishing Psoriatic Arthritis and Fibromyalgia. <i>Journal of Rheumatology</i> , 2012, 39, 849-855.	2.0	94
300	Patient-reported Outcomes in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2012, 39, 795-803.	2.0	64
301	Adalimumab in Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2012, 89, 77-81.	2.2	10
302	Clinical features of polymyalgia rheumatica and giant cell arteritis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 509-521.	8.0	185
303	Retroperitoneal fibrosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 439-448.	3.3	51
304	Primary central nervous system vasculitis: pathology and mechanisms. <i>Acta Neuropathologica</i> , 2012, 123, 759-772.	7.7	130
305	Comparison of CNS vasculitis in children and adults; is this the same disease entity. <i>Pediatric Rheumatology</i> , 2012, 10, .	2.1	0
306	Is the nail psoriasis severity index reliable in the assessment of nail psoriasis by rheumatologists?. <i>Arthritis Care and Research</i> , 2012, 64, 455-458.	3.4	23

#	ARTICLE	IF	CITATIONS
307	Small vessel vasculitis surrounding an uninfamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: Two subsets of giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 549-556.	6.7	69
308	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Arthritis and Rheumatism</i> , 2012, 64, 943-954.	6.7	273
309	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 344-353.	6.4	182
310	Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S139-61.	0.8	6
311	Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 776-8.	0.8	22
312	Possibile mixoma endoventricolare sinistro in paziente con TVP degli arti inferiori: considerazioni da un caso clinico. <i>Italian Journal of Medicine</i> , 2011, 5, 184-189.	0.3	1
313	Idiopathic aortitis: an underrecognized vasculitis. <i>Arthritis Research and Therapy</i> , 2011, 13, 119.	3.5	25
314	Chronic Periaortitis (CP). <i>Medical Radiology</i> , 2011, , 175-185.	0.1	0
315	Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. <i>Lancet</i> , The, 2011, 378, 338-346.	13.7	189
316	Recommendations for the appropriate use of anti-TNF $\alpha$ therapy in patients with psoriatic arthritis. <i>Reumatismo</i> , 2011, 56, .	0.9	2
317	CLINICAL ASSESSMENT IN PSORIATIC ARTHRITIS. <i>Reumatismo</i> , 2011, 59, 68-72.	0.9	0
318	Chronic periaortitis: a large-vessel vasculitis?. <i>Current Opinion in Rheumatology</i> , 2011, 23, 1-6.	4.3	73
319	Vasculitis of the Gastrointestinal Tract in Chronic Periaortitis. <i>Medicine (United States)</i> , 2011, 90, 28-39.	1.0	24
320	Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 447-453.	0.9	81
321	Aortitis and periaortitis in ankylosing spondylitis. <i>Joint Bone Spine</i> , 2011, 78, 451-455.	1.6	54
322	New indications for biological therapies. <i>Internal and Emergency Medicine</i> , 2011, 6, 1-9.	2.0	7
323	Comparison of CNS vasculitis in children and adults; is this the same disease entity. <i>Pediatric Rheumatology</i> , 2011, 9, .	2.1	0
324	Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2097-2104.	6.7	31

#	ARTICLE	IF	CITATIONS
325	Primary central nervous system vasculitis presenting with intracranial hemorrhage. <i>Arthritis and Rheumatism</i> , 2011, 63, 3598-3606.	6.7	61
326	A putative functional variant within the <i>UBAC2</i> gene is associated with increased risk of Behçet's disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 3607-3612.	6.7	39
327	Aortite et pñriaortite dans la spondylarthrite ankylosante. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2011, 78, 227-231.	0.0	0
328	Rapidly progressive primary central nervous system vasculitis. <i>Rheumatology</i> , 2011, 50, 349-358.	1.9	50
329	CC chemokine receptor 5 polymorphism in chronic periaortitis. <i>Rheumatology</i> , 2011, 50, 1025-1032.	1.9	25
330	Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study. <i>Journal of Rheumatology</i> , 2011, 38, 898-903.	2.0	101
331	Imaging findings in primary central nervous system vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S104-9.	0.8	15
332	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S7-14.	0.8	23
333	The causes of uveitis in a referral centre of Northern Italy. <i>International Ophthalmology</i> , 2010, 30, 521-529.	1.4	61
334	Primary central nervous system vasculitis: Is it a single disease?. <i>Annals of Neurology</i> , 2010, 68, 573-574.	5.3	11
335	An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 578-586.	2.4	12
336	Psoriatic disease: concepts and implications. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 627-630.	2.4	24
337	G/R 241 Polymorphism of Intercellular Adhesion Molecule 1 ( <i>ICAM-1</i> ) Is Associated with Fuchs Uveitis. , 2010, 51, 4447.		11
338	Localized vasculitis of the gastrointestinal tract: a case series. <i>Rheumatology</i> , 2010, 49, 1326-1335.	1.9	54
339	Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. <i>Rheumatology</i> , 2010, 49, 1107-1111.	1.9	37
340	Comment on: Longitudinal examination with shoulder ultrasound in patients with polymyalgia rheumatica: reply. <i>Rheumatology</i> , 2010, 49, 1998-1999.	1.9	2
341	Differential effects of anti-TNF-Å drugs on fibroblast-like synoviocyte apoptosis. <i>Rheumatology</i> , 2010, 49, 480-489.	1.9	34
342	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1744-1750.	0.9	139

#	ARTICLE	IF	CITATIONS
343	Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis involving the central nervous system: case report and review of the literature. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 759-66.	0.8	16
344	Synovial expression of cell adhesion molecules in polymyalgia rheumatica. <i>Clinical and Experimental Immunology</i> , 2009, 107, 494-500.	2.6	3
345	Clinical features and epidemiology of spondyloarthritis associated with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 2449.	3.3	107
346	Psoriatic Arthritis Spondylitis Radiology Index: A Modified Index for Radiologic Assessment of Axial Involvement in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 1006-1011.	2.0	47
347	Multidisciplinary Focus on Cyclosporin A. <i>Journal of rheumatology Supplement, The</i> , 2009, 83, 52-55.	2.2	5
348	Comment on: Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis: reply. <i>Rheumatology</i> , 2009, 48, 1180-1180.	1.9	3
349	Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. <i>Rheumatology</i> , 2009, 48, 1566-1569.	1.9	55
350	Criteria, Frequency, and Duration of Clinical Remission in Psoriatic Arthritis Patients with Peripheral Involvement Requiring Second-line Drugs. <i>Journal of rheumatology Supplement, The</i> , 2009, 83, 78-80.	2.2	15
351	Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor $\pm$ therapy: Is there a need for more comprehensive screening procedures?. <i>Arthritis and Rheumatism</i> , 2009, 61, 801-812.	6.7	39
352	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1235-1242.	6.7	104
353	Tuberculous uveitis, a resurgent and underdiagnosed disease. <i>International Ophthalmology</i> , 2009, 29, 67-74.	1.4	67
354	Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2009, 36, 1256-1264.	2.0	47
355	EULAR recommendations for the management of primary small and medium vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 310-317.	0.9	889
356	EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 318-323.	0.9	596
357	Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1528-1534.	0.9	166
358	Biopsy Findings in Primary Angiitis of the Central Nervous System. <i>American Journal of Surgical Pathology</i> , 2009, 33, 35-43.	3.7	170
359	Giant Cell Arteritis and Polymyalgia Rheumatica. , 2009, , 285-304.		166
360	Toll-like receptor 4 (TLR4) gene polymorphisms in giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, S40-4.	0.8	9

#	ARTICLE	IF	CITATIONS
361	Toll-like receptor 4 (TLR4) gene polymorphisms in Italian patients with Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, S43-7.	0.8	11
362	Fast spin echo-T2-weighted sequences with fat saturation in toe dactylitis of spondyloarthritis. <i>Clinical Rheumatology</i> , 2008, 27, 1141-1145.	2.2	21
363	Primary central nervous system vasculitis with prominent leptomeningeal enhancement: A subset with a benign outcome. <i>Arthritis and Rheumatism</i> , 2008, 58, 595-603.	6.7	91
364	Efficacy of tumor necrosis factor $\alpha$ blockade in primary central nervous system vasculitis resistant to immunosuppressive treatment. <i>Arthritis and Rheumatism</i> , 2008, 59, 291-296.	6.7	58
365	Infliximab for the treatment of Neuro-Behçet's disease: A case series and review of the literature. <i>Arthritis and Rheumatism</i> , 2008, 59, 285-290.	6.7	127
366	Serum interleukin-6 receptor in polymyalgia rheumatica: A potential marker of relapse/recurrence risk. <i>Arthritis and Rheumatism</i> , 2008, 59, 1147-1154.	6.7	23
367	The role of infectious agents in the pathogenesis of vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 897-911.	3.3	29
368	Role of imaging in vasculitis and connective tissue diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 1075-1091.	3.3	26
369	Wegener Granulomatosis with Spleen Infarction: Case Report and Review of the Literature. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 328-333.	3.4	23
370	Diagnosis and Treatment of Giant Cell Arteritis. <i>Drugs and Aging</i> , 2008, 25, 281-297.	2.7	34
371	Polymyalgia rheumatica and giant-cell arteritis. <i>Lancet, The</i> , 2008, 372, 234-245.	13.7	674
372	EULAR recommendations for the management of Behçet disease. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1656-1662.	0.9	624
373	Primary CNS vasculitis with spinal cord involvement. <i>Neurology</i> , 2008, 70, 2394-2400.	1.1	118
374	$\alpha$ 463 G/A myeloperoxidase promoter polymorphism in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 485-488.	0.9	18
375	Cervical interspinous bursitis in active polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 758-761.	0.9	88
376	Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy. <i>Rheumatology</i> , 2008, 47, 1671-1677.	1.9	111
377	The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. <i>Rheumatology</i> , 2008, 47, 1664-1670.	1.9	80
378	Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. <i>Rheumatology</i> , 2008, 47, 872-876.	1.9	71



#	ARTICLE	IF	CITATIONS
379	Chronic Periaortitis. <i>Circulation</i> , 2008, 118, 1214-1216.	1.6	14
380	Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. <i>Rheumatology</i> , 2008, 48, 250-253.	1.9	134
381	Pericarditis heralding Erdheim-Chester Disease. <i>Circulation</i> , 2008, 118, e511-2.	1.6	22
382	Angiography-Negative Primary Central Nervous System Vasculitis. <i>Medicine (United States)</i> , 2008, 87, 264-271.	1.0	95
383	Improving therapeutic options for patients with giant cell arteritis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 17-22.	4.3	34
384	Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. <i>Journal of Rheumatology</i> , 2008, 35, 270-7.	2.0	61
385	Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, 395-400.	0.8	34
386	Initiative for quality in psoriasis and psoriatic arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1431-3.	2.0	2
387	1T magnetic resonance imaging in the diagnosis of giant cell arteritis: comparison with ultrasonography and physical examination of temporal arteries. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, S76-80.	0.8	17
388	Prominent perivascular enhancement in primary central nervous system vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, S111.	0.8	15
389	Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 577-579.	0.9	13
390	Isolated knee monoarthritis heralding resectable non-small-cell lung cancer. A paraneoplastic syndrome not previously described. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1672-1674.	0.9	8
391	Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF- $\kappa$ B pathway. <i>Rheumatology</i> , 2007, 46, 1252-1257.	1.9	20
392	Peripheral inflammatory arthritis in patients with chronic periaortitis: report of five cases and review of the literature. <i>Rheumatology</i> , 2007, 47, 315-318.	1.9	23
393	Lack of association of the 463 G/A myeloperoxidase promoter polymorphism with Behcet's disease in Italian patients. <i>Rheumatology</i> , 2007, 46, 1547-1550.	1.9	5
394	Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. <i>Rheumatology</i> , 2007, 47, 403-408.	1.9	221
395	Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica. <i>Annals of Internal Medicine</i> , 2007, 146, 631.	3.9	158
396	Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis. <i>Annals of Internal Medicine</i> , 2007, 146, 621.	3.9	491

#	ARTICLE	IF	CITATIONS
397	Retroperitoneal Fibrosis: Evolving Concepts. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 803-817.	1.9	74
398	Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. <i>Rheumatology</i> , 2007, 46, 1161-1164.	1.9	153
399	Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: A seventeen-year population-based study. <i>Arthritis and Rheumatism</i> , 2007, 57, 171-178.	6.7	100
400	PLA1/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3502-3508.	6.7	18
401	Treatment of refractory polymyalgia rheumatica with etanercept: An open pilot study. <i>Arthritis and Rheumatism</i> , 2007, 57, 1514-1519.	6.7	52
402	Primary central nervous system vasculitis: analysis of 101 patients. <i>Annals of Neurology</i> , 2007, 62, 442-451.	5.3	543
403	Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases. <i>Rheumatology International</i> , 2007, 27, 927-933.	3.0	40
404	Giant-cell arteritis of the female genital tract associated with occult temporal arteritis and FDG-PET evidence of large-vessel vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2007, 25, S36-9.	0.8	5
405	Retroperitoneal fibrosis. <i>Lancet, The</i> , 2006, 367, 241-251.	13.7	612
406	Systemic vasculitis: state of the art and emerging concepts. <i>Current Opinion in Rheumatology</i> , 2006, 18, 1-2.	4.3	3
407	New approaches in the treatment of Adamantiades-Behçet's disease. <i>Current Opinion in Rheumatology</i> , 2006, 18, 3-9.	4.3	79
408	Chronic periaortitis and HLA-DRB1*03: Another clue to an autoimmune origin. <i>Arthritis and Rheumatism</i> , 2006, 55, 126-130.	6.7	102
409	Interleukin-10 promoter polymorphisms in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 4011-4017.	6.7	40
410	Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: Results of a fifty-four-week study. <i>Arthritis and Rheumatism</i> , 2006, 55, 812-816.	6.7	44
411	Giant cell arteritis: Involvement of intracranial arteries. <i>Arthritis and Rheumatism</i> , 2006, 55, 985-989.	6.7	147
412	Primary Sjogren's syndrome associated with chronic periaortitis. <i>Rheumatology</i> , 2006, 46, 719-720.	1.9	15
413	Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2006, 24, 70-8.	0.8	11
414	Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. <i>Journal of Rheumatology</i> , 2006, 33, 703-8.	2.0	58

#	ARTICLE	IF	CITATIONS
415	Tumor necrosis factor-alpha protects synovial cells from nitric oxide induced apoptosis through phosphoinositide 3-kinase Akt signal transduction. <i>Journal of Rheumatology</i> , 2006, 33, 1061-8.	2.0	24
416	Long-term outcome of giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2006, 24, S65-70.	0.8	3
417	Are steroids alone sufficient for the treatment of giant cell arteritis?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 277-292.	3.3	25
418	Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: A prospective followup study. <i>Arthritis and Rheumatism</i> , 2005, 53, 33-38.	6.7	136
419	<sup>18</sup> F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis. <i>Arthritis and Rheumatism</i> , 2005, 53, 122-125.	6.7	65
420	Takayasu's arteritis: A study of 104 Italian patients. <i>Arthritis and Rheumatism</i> , 2005, 53, 100-107.	6.7	273
421	Positron emission tomography (PET): Evaluation of chronic periaortitis. <i>Arthritis and Rheumatism</i> , 2005, 53, 298-303.	6.7	128
422	Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2005, 53, 293-297.	6.7	218
423	Behçet's disease and cardiovascular involvement. <i>Lupus</i> , 2005, 14, 723-726.	1.6	93
424	Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent "scar" ? A study using <sup>18</sup> F-fluorodeoxyglucose positron emission tomography. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, 231-4.	0.8	46
425	Inflammatory changes of hip synovial structures in polymyalgia rheumatica. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, 462-8.	0.8	66
426	Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis. <i>Journal of Rheumatology</i> , 2005, 32, 2173-7.	2.0	23
427	Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1594-1600.	0.9	267
428	Thalidomide, deep venous thrombosis and vasculitis. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2062-2063.	3.8	5
429	Are polymyalgia rheumatica and giant cell arteritis the same disease?. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 294-301.	3.4	130
430	Polymyalgia rheumatica. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 705-722.	3.3	80
431	Soluble Receptor Activator of Nuclear Factor- $\kappa$ B Ligand (sRANKL)/Osteoprotegerin Balance in Ageing and Age-Associated Diseases. <i>Biogerontology</i> , 2004, 5, 119-127.	3.9	24
432	Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. <i>Arthritis and Rheumatism</i> , 2004, 51, 264-268.	6.7	241

#	ARTICLE	IF	CITATIONS
433	Prednisone plus Methotrexate for Polymyalgia Rheumatica. <i>Annals of Internal Medicine</i> , 2004, 141, 493.	3.9	204
434	Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica. <i>Journal of Rheumatology</i> , 2004, 31, 120-4.	2.0	24
435	Geographical and genetic factors do not account for significant differences in the clinical spectrum of giant cell arteritis in southern europe. <i>Journal of Rheumatology</i> , 2004, 31, 520-3.	2.0	10
436	Vascular endothelial growth factor gene polymorphisms in Behçet's disease. <i>Journal of Rheumatology</i> , 2004, 31, 1785-9.	2.0	62
437	Clinical manifestations of Behçet's disease in 137 Italian patients: results of a multicenter study. <i>Clinical and Experimental Rheumatology</i> , 2004, 22, S46-51.	0.8	30
438	<sup>18</sup> F-Fluorodeoxyglucose-positron emission tomography: A new explorative perspective. <i>Experimental Gerontology</i> , 2003, 38, 463-470.	2.8	27
439	Efficacy of infliximab in resistant psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 541-545.	6.7	59
440	Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 3219-3223.	6.7	35
441	Cardiac Involvement in Systemic Vasculitis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003, 1, 227-254.	0.1	0
442	Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. <i>Journal of Rheumatology</i> , 2003, 30, 760-3.	2.0	50
443	Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. <i>Journal of Rheumatology</i> , 2003, 30, 2160-4.	2.0	50
444	Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2003, 21, S23-8.	0.8	61
445	Successful treatment of SAPHO syndrome with infliximab: report of two cases. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 375-376.	0.9	112
446	Is Duplex Ultrasonography Useful for the Diagnosis of Giant-Cell Arteritis?. <i>Annals of Internal Medicine</i> , 2002, 137, 232.	3.9	169
447	Polymyalgia Rheumatica and Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2002, 347, 261-271.	27.0	1,002
448	Renal cell carcinoma mimicking polymyalgia rheumatica. <i>Scandinavian Journal of Rheumatology</i> , 2002, 31, 103-103.	1.1	20
449	Seronegative spondyloarthritides. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 723-739.	3.3	65
450	Detection of parvovirus B19 DNA by polymerase chain reaction in giant cell arteritis: A case-control study. <i>Arthritis and Rheumatism</i> , 2002, 46, 3099-3101.	6.7	45

#	ARTICLE	IF	CITATIONS
451	Fast spin echo-T2-weighted sequences with fat saturation in dactylitis of spondylarthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 2964-2967.	6.7	65
452	Cortisol, Dehydroepiandrosterone Sulfate, and Androstenedione Levels in Patients with Polymyalgia Rheumatica during Twelve Months of Glucocorticoid Therapy. <i>Annals of the New York Academy of Sciences</i> , 2002, 966, 91-96.	3.8	23
453	Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease. <i>Journal of Rheumatology</i> , 2002, 29, 535-40.	2.0	39
454	Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6. <i>Journal of Rheumatology</i> , 2002, 29, 748-56.	2.0	25
455	Musculoskeletal Manifestations in a Population-based Cohort of Inflammatory Bowel Disease Patients. <i>Scandinavian Journal of Gastroenterology</i> , 2001, 36, 1307-1313.	1.5	144
456	Ankylosing spondylitis and undifferentiated spondyloarthropathies: a clinical review and description of a disease subset with older age at onset. <i>Current Opinion in Rheumatology</i> , 2001, 13, 280-284.	4.3	46
457	Giant cell arteritis with low erythrocyte sedimentation rate: Frequency of occurrence in a population-based study. <i>Arthritis and Rheumatism</i> , 2001, 45, 140-145.	6.7	254
458	Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. <i>Arthritis and Rheumatism</i> , 2001, 44, 1155-1159.	6.7	47
459	Treatment of longstanding active giant cell arteritis with infliximab: Report of four cases. <i>Arthritis and Rheumatism</i> , 2001, 44, 2933-2935.	6.7	207
460	Retrocalcaneal bursitis in polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 1160-1161.	0.9	4
461	Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. <i>Journal of Rheumatology</i> , 2001, 28, 1049-55.	2.0	101
462	Distal extremity swelling with pitting edema in psoriatic arthritis: a case-control study. <i>Clinical and Experimental Rheumatology</i> , 2001, 19, 291-6.	0.8	24
463	Association of MICA alleles and HLA-B51 in Italian patients with Behçet's disease. <i>Journal of Rheumatology</i> , 2001, 28, 1867-70.	2.0	37
464	Vascular endothelial growth factor production in polymyalgia rheumatica. <i>Arthritis and Rheumatism</i> , 2000, 43, 2472-2480.	6.7	32
465	Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: A prospective follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2000, 30, 17-24.	3.4	178
466	Musculoskeletal manifestations in inflammatory bowel disease. <i>European Journal of Internal Medicine</i> , 2000, 11, 210-214.	2.2	16
467	Thrombosis associated with the prothrombin G→A20210 mutation in Behçet's disease. <i>Journal of Rheumatology</i> , 2000, 27, 515-6.	2.0	15
468	Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. <i>Journal of Rheumatology</i> , 2000, 27, 1215-21.	2.0	50

#	ARTICLE	IF	CITATIONS
469	Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. <i>Journal of Rheumatology</i> , 2000, 27, 1470-6.	2.0	28
470	RS3PE syndrome: an overview. <i>Clinical and Experimental Rheumatology</i> , 2000, 18, S53-5.	0.8	60
471	The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. <i>Journal of Rheumatology</i> , 2000, 27, 2179-84.	2.0	96
472	Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica. <i>Clinical and Experimental Rheumatology</i> , 2000, 18, 591-5.	0.8	8
473	Polymyalgia manifestations in different conditions mimicking polymyalgia rheumatica. <i>Clinical and Experimental Rheumatology</i> , 2000, 18, 755-9.	0.8	29
474	HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 303-308.	0.9	44
475	Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 230-236.	0.9	113
476	RS3PE: six years later. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 722-723.	0.9	9
477	Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1259-1266.	6.7	72
478	Polymyalgia rheumatica: a disorder of extraarticular synovial structures?. <i>Journal of Rheumatology</i> , 1999, 26, 517-21.	2.0	34
479	Diagnostic approach in a patient presenting with polymyalgia. <i>Clinical and Experimental Rheumatology</i> , 1999, 17, 276-8.	0.8	26
480	HLA-DRB1, DQA1, and DQB1 alleles associated with giant cell arteritis in northern Italy. <i>Journal of Rheumatology</i> , 1999, 26, 2395-9.	2.0	15
481	Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. <i>Clinical and Experimental Rheumatology</i> , 1999, 17, 741-4.	0.8	30
482	Distal musculoskeletal manifestations in polymyalgia rheumatica: A prospective followup study. <i>Arthritis and Rheumatism</i> , 1998, 41, 1221-1226.	6.7	141
483	The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A. <i>Rheumatology International</i> , 1998, 18, 27-33.	3.0	22
484	Diagnosis and Management of Polymyalgia Rheumatica/Giant Cell Arteritis. <i>BioDrugs</i> , 1998, 9, 25-32.	4.6	3
485	Psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 1998, 10, 299-305.	4.3	28
486	Dactylitis also involving the synovial sheaths in the palm of the hand: two more cases studied by magnetic resonance imaging. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 61-62.	0.9	20

#	ARTICLE	IF	CITATIONS
487	Erythrocyte Sedimentation Rate and C-Reactive Protein in the Diagnosis of Polymyalgia Rheumatica. <i>Annals of Internal Medicine</i> , 1998, 128, 873.	3.9	16
488	Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica. <i>Clinical and Experimental Rheumatology</i> , 1998, 16, 263-8.	0.8	8
489	Remitting distal lower extremity swelling with pitting oedema in acute sarcoidosis. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 565-566.	0.9	26
490	Diagnostic and classification criteria, clinical and functional assessment, and therapeutic advances for spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 1997, 9, 284-290.	4.3	17
491	Polymyalgia rheumatica. <i>Lancet, The</i> , 1997, 350, 43-47.	13.7	64
492	Proximal Bursitis in Active Polymyalgia Rheumatica. <i>Annals of Internal Medicine</i> , 1997, 127, 27.	3.9	120
493	Therapy with cyclosporine in psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1997, 27, 36-43.	3.4	35
494	Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. <i>Arthritis and Rheumatism</i> , 1997, 40, 1873-1878.	6.7	222
495	Synovial expression of cell adhesion molecules in polymyalgia rheumatica. <i>Clinical and Experimental Immunology</i> , 1997, 107, 494-500.	2.6	20
496	Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases?. <i>Journal of Rheumatology</i> , 1997, 24, 249-52.	2.0	36
497	Isolated peripheral enthesitis and/or dactylitis: a subset of psoriatic arthritis. <i>Journal of Rheumatology</i> , 1997, 24, 1106-10.	2.0	42
498	Polymyalgia rheumatica. <i>Lancet, The</i> , 1996, 348, 550-551.	13.7	20
499	Polyarteritis nodosa and HIV infection: No evidence of a direct pathogenic role of HIV. <i>Infection</i> , 1996, 24, 159-161.	4.7	18
500	Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report of nineteen cases. <i>Arthritis and Rheumatism</i> , 1996, 39, 73-80.	6.7	122
501	Giant cell arteritis and amyloidosis: comment on the article by Salvarani et al. <i>Arthritis and Rheumatism</i> , 1996, 39, 1073-1074.	6.7	0
502	Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. <i>Arthritis and Rheumatism</i> , 1996, 39, 1199-1207.	6.7	107
503	CD8 LYMPHOCYTE SUBSETS IN ACTIVE POLYMYALGIA RHEUMATICA: COMPARISON WITH ELDERLY-ONSET AND ADULT RHEUMATOID ARTHRITIS AND INFLUENCE OF PREDNISON THERAPY. <i>Rheumatology</i> , 1996, 35, 642-648.	1.9	20
504	The Incidence of Giant Cell Arteritis in Olmsted County, Minnesota: Apparent Fluctuations in a Cyclic Pattern. <i>Annals of Internal Medicine</i> , 1995, 123, 192.	3.9	291



#	ARTICLE	IF	CITATIONS
505	Polymyalgia rheumatica and giant cell arteritis. Bailliere's Clinical Rheumatology, 1995, 9, 515-527.	1.0	13
506	Epidemiology of polymyalgia rheumatica in olmsted county, minnesota, 1970â€“1991. Arthritis and Rheumatism, 1995, 38, 369-373.	6.7	175
507	Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.. Annals of the Rheumatic Diseases, 1995, 54, 640-644.	0.9	28
508	Prevalence of psoriatic arthritis in Italian psoriatic patients. Journal of Rheumatology, 1995, 22, 1499-503.	2.0	78
509	On the utility of CD8 level assessment in the diagnosis of polymyalgia rheumatica/giant cell arteritis. Clinical and Experimental Rheumatology, 1995, 13, 129-30.	0.8	5
510	This letter was shown to Dr. Macchioni et al. who reply. Rheumatology, 1994, 33, 195-195.	1.9	0
511	Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. Arthritis and Rheumatism, 1994, 37, 1621-1626.	6.7	79
512	Elevated soluble intercellular adhesion molecule 1 in the serum of patients with polymyalgia rheumatica: influence of steroid treatment. Journal of Rheumatology, 1994, 21, 1860-4.	2.0	16
513	Serum soluble CD4 and CD8 levels in polymyalgia rheumatica. Journal of Rheumatology, 1994, 21, 1865-9.	2.0	12
514	LYMPHOCYTE SUBPOPULATIONS ANALYSIS IN PERIPHERAL BLOOD IN POLYMYALGIA RHEUMATICA/GLANT CELL ARTERITIS. Rheumatology, 1993, 32, 666-670.	1.9	22
515	Incidence of Stroke in Young Adults in the Reggio Emilia Area, Northern Italy. Neuroepidemiology, 1993, 12, 82-87.	2.3	31
516	Synovitis in Polymyalgia Rheumatica: An Immunogenetic Study. Rheumatology, 1992, 31, 720-720.	1.9	4
517	The cervical spine in patients with psoriatic arthritis: a clinical, radiological and immunogenetic study.. Annals of the Rheumatic Diseases, 1992, 51, 73-77.	0.9	70
518	Anticardiolipin antibodies in northern italian population with PMR/GCA. American Journal of Medicine, 1992, 92, 712-713.	1.5	11
519	Giant cell arteritis in Mediterranean countries: Comment on the article by Salvarani et al. Arthritis and Rheumatism, 1992, 35, 1249-1250.	6.7	9
520	Immunologic effects in patients with psoriatic arthritis treated with cyclosporine A. Journal of Rheumatology, 1992, 19, 1933-7.	2.0	3
521	Soluble interleukin 2 receptors in polymyalgia rheumatica/giant cell arteritis. Clinical and laboratory correlations. Journal of Rheumatology, 1992, 19, 1100-6.	2.0	17
522	Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy. Journal of Rheumatology, 1992, 19, 74-9.	2.0	39

#	ARTICLE	IF	CITATIONS
523	Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. <i>Arthritis and Rheumatism</i> , 1991, 34, 351-356.	6.7	198
524	The role of interleukin 1, erythropoietin and red cell bound immunoglobulins in the anaemia of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 1991, 9, 241-6.	0.8	19
525	Clinical response to auranofin in patients with psoriatic arthritis. <i>Clinical Rheumatology</i> , 1989, 8, 54-57.	2.2	13
526	Hypothyroidism Simulating Polymyositis. <i>Scandinavian Journal of Rheumatology</i> , 1988, 17, 147-149.	1.1	9
527	Anticardiolipin antibodies in a case of neuro-Behçet with superior vena caval occlusion. <i>Clinical Rheumatology</i> , 1987, 6, 88-91.	2.2	6
528	Synovitis in polymyalgia rheumatica: a 5-year followup study in Reggio Emilia, Italy. <i>Journal of Rheumatology</i> , 1987, 14, 1209-10.	2.0	6
529	Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. <i>Clinical and Experimental Rheumatology</i> , 1987, 5, 205-15.	0.8	66
530	Nephrotic syndrome induced by tiopronin: Association with the HLA-DR3 antigen. <i>Arthritis and Rheumatism</i> , 1985, 28, 595-596.	6.7	5